In recent years, the momentum created by the initial effectiveness of chimeric antigen receptor (CAR) T-cell therapy has prompted team-based research efforts in cellular therapy at Cleveland Clinic.
The immune checkpoint inhibitor and anti-PD-L1 monoclonal antibody pembrolizumab improves relapse-free survival but not overall survival when compared with other adjuvant treatments for patients with high-risk resected melanoma.
A 35-year-old presents with an asymptomatic elevated pigmented lesion in the left eye, with nodularity along the pupillary margin but with no feeder vessels or neovascularization.
Dermatologic complications are common in lung transplant recipients, and early treatment for suspicious lesions is crucial in this population. Learn more about five different types of cutaneous complications.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
As lung transplants become more common, clinicians should be aware of post-transplant dermatologic complications including melanoma.
The 31-GEP identifies low-risk patients most likely to benefit from intensive surveillance and adjuvant therapy.
Dr. Funchain applies practical translation of genomic data to clinical precision oncology, melanoma survivorship and predictors of clinical outcomes and adverse events related to immunotherapy.
Investigating tumor mutational burden, specific driver mutations, immune-related RNA expression data and various clinicopathologic features from 479 tumors to find correlations with clinical characteristics and outcomes.
Cleveland Clinic experts will address important advances in the treatment of melanoma in this complimentary one-day symposium.